Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder

Wednesday, Biogen Inc. (NASDAQ:BIIB) revealed topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen in treatment-naïve, symptomatic infants with spinal muscular atrophy (SMA). The investigational higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every four months, compared to the approved nusinersen 12 mg regimen (Spinraza). Also Read: Eli Lilly’s Alzheimer’s Drug Faces UK Agency Block After ...